We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Misleading Claims, Risk Omission in Covis Promotion Prompts Untitled Letter
Misleading Claims, Risk Omission in Covis Promotion Prompts Untitled Letter
Covis Pharmaceuticals has received an FDA untitled letter for making unsubstantiated superiority claims and omitting vital risk information about its heart drug Lanoxin in a physician letter.